ClinicalTrials.gg
RecruitingNCT06136611PORTRAITUpdated May 8, 2026

Preoperative Preradiotherapy TTFields

An interventional study of TTFields in Glioblastoma, sponsored by The Christie NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by The Christie NHS Foundation Trust · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies in Glioblastoma with a site in United Kingdom — 24 open to participants now, 34 under way, 5 of them phase 3. Glioblastoma · United Kingdom.

Planned enrollment
53rd of 75
42 · median 111
Started
2024
with 7 others
No phase
6 of 86
4 open now
Primary completion
2026-09
later than 9 of 33 live
Registered
63rd of 86
by date

Among the 86 studies in Glioblastoma with a site in United Kingdom, this one is the 53rd largest by planned enrollment of the 75 interventional ones that give a count, is one of 8 that started in 2024, is one of 6 with no phase, reaches primary completion later than 9 of the 33 other live ones, and was the 63rd registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

24 of the 86 studies in Glioblastoma with a site in United Kingdom are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Glioblastoma with a site in United Kingdom, or all of them as a file.
02

Study summary

PreOperative PreRAdIotherapy Tumour Treating Fields (PORTRAIT) is a Phase I study that will test the safety and feasibility of Optune administered preoperatively and preradiotherapy in patients with a new radiological diagnosis of glioblastoma (GBM). Participants will be required to undergo additional MRI sequencing scans and provide blood, tear fluid and tissue samples over a maximum of 6 months. After the study patients will follow their standard treatment pathway.

Read the detailed description

Glioblastoma is the most common primary malignant brain tumour in adults. Its outcomes are poor due to local disease progression in most patients. Current treatment includes surgery followed by chemotherapy and radiotherapy 4-6 weeks after surgery. In this time interval, some tumour cells do not receive any treatment. Furthermore, studies show that around half of all glioblastoma patients experience rapid early progression (REP) i.e. growth of the tumour in the time interval between surgery and postoperative chemotherapy/radiotherapy. REP is associated with a shorter survival and there are currently no effective treatments or preventative measures to address it.

Tumour Treating Fields (TTFields), also known as Optune, is a locally applied treatment modality that has contributed to a better survival outcome for glioblastoma patients when used after surgery and chemo-radiotherapy. The investigators hypothesize that earlier treatment using the Optune device before the surgery and between the surgery and postoperative radiotherapy can prevent REP and improve patient outcome. The PORTRAIT (PreOpeRaTive pRerAdIotherapy Ttfields) phase 1 trial will test the safety and feasibility of Optune treatment before surgery and before post-operative radiotherapy in a maximum of 14 patients. Participants will be required to undergo additional MRI sequencing scans and provide blood, tear fluid and tissue samples over a maximum of 6 months.

A non-experimental arm (Non-EA) of 28 patients will allow comparisons of data collected from PORTRAIT experimental arm patients with comparable Standard of Care (SoC) treated patients from the same time frame. This will maximise PORTRAIT's translational and clinically relevant components.

Participants will be invited to the research study if they are over the age of 35 and have a new radiological diagnosis of glioblastoma. All recruitment and treatment will be conducted at the Christie NHS Foundation Trust and Northern Care Alliance NHS Foundation Trust.

The study is funded by a research grant from Novocure.

03

Conditions studied

  • Glioblastoma

Browse trials for

Keywords

  • Neoadjuvant
  • Preoperative
  • Tumour Treating Fields
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is aged >35 years (age range of more likely to suffer from an IDHwt World Health Organisation (WHO) grade 4 astrocytoma)*
  • Patient is male or female.
  • Patient has a new radiological diagnosis of glioblastoma.
  • Patient has a performance status judged by WHO, (ECOG) score = 0-1.
  • Patient has been reviewed by Neuro-oncology multidisciplinary team (MDT - neurosurgeon, clinical oncologist, radiologist and pathologist); MDT consensus that offering study entry is clinically appropriate and safe i.e. patient unlikely to come to harm (e.g. hydrocephalus) from delayed surgery and pre-operative Optune based on available clinical information and imaging.
  • PI has confirmed at the first clinic visit that study entry is clinically appropriate and safe (e.g. lack of severe and debilitating symptoms of raised intracranial pressure).
  • There is intention to treat the patient with surgical resection and postoperative therapy as per current standard of care (40Gy/15 fr or 60Gy/30fr).
  • Patient has adequate haematological and biochemical parameters for surgery and contrast agent administration (full blood count and coagulation profile deemed acceptable by clinical team, >30ml/min).
  • Patient has mental capacity to consent for treatment.
  • Patient is able and willing to give

Criteria specific to the experimental arm:

  • Patient is able and willing to comply with study protocol requirements to continuously shave their head
  • Patient is able and willing to comply with study protocol requirements to wear Optune equipment for the required duration.

Exclusion criteria

Exclusion Criteria:

  • Patients with uncontrolled seizures.
  • Patients are due to undergo a planned procedure only.
  • Patients have a suspicion of other tumour on CT body scan or known except non-melanoma skin cancer, completely resected or prostate cancer (with Prostate Specific Antigen of less than or equal to 0.1 ng/ml) within the past three years.
  • Patients have to contrast-enhanced MRI scanning (e.g. claustrophobia, gadolinium allergy).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Optune

    Patients will apply TTFields (a treatment device referred to as Optune) before surgery and continue using this once the stitches are removed (approximately one to two weeks after surgery). Patients will wear the Optune application for 2 to 3 weeks before their standard-of-care (SoC) surgery and 3 to 4 weeks after the surgery (while awaiting their postoperative radiotherapy). Treatment with TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.

    Device: TTFields

  • No intervention
    Non-Experimental Arm

    Patients will follow the routine care pathway for glioblastoma and timings of the following will be determined by the clinical team.

Interventions

  • DeviceTTFields

    TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.

06

What researchers measure

Primary outcomes

  1. To determine the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of Pre-Operative and Pre-Radiotherapy TTFields additional to the standard treatment of care (SoC) including adjuvant TTFields.

    This endpoint will be tested by skin toxicity / wound complications. Toxicity is defined using CTCAE v5.0 and study related complications are defined as; * Skin toxicity grade 3 or higher * Wound closure or wound healing problems grade 2 or higher that are possibly related to TTFields treatment

    Time frame: 18 months

  2. To determine the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of Pre-Operative and Pre-Radiotherapy TTFields additional to the standard treatment of care (SoC) including adjuvant TTFields.

    This endpoint will be tested by alterations to the original date of surgery and the start of the postoperative radiotherapy; Study related complications will be defined as; * Change of surgery date due to symptoms related to the tumour that are possibly related to the TTFields treatment * Delay of start of the postoperative radiotherapy (RT) possibly related to the TTFields treatment (later than 6 weeks postoperative)

    Time frame: 18 months

Secondary outcomes

  1. Concordance between MRI based diagnosis of glioblastoma and definitive histological diagnosis

    Evaluate the use of MRI to select glioblastoma patients for PORTRAIT without pathological confirmation.

    Time frame: 18 months

  2. REP: tumour volume difference between the post-operative MRI and pre-radiotherapy MRI.

    Evaluate the effect of TTFields on REP - tumour growth between surgery and postoperative chemoradiotherapy, in patients with a new diagnosis of glioblastoma. A lower value represents a better outcome.

    Time frame: 18 months

  3. Registration of postoperative surgical complications

    Postoperative surgical complications (e.g. haemorrhage, wound infection, delayed wound healing, seizures). Lower registrations represents a better outcome.

    Time frame: 18 months

  4. Registration of radiotherapy related complications

    Radiotherapy related complications (e.g. radiation necrosis). Lower registrations represents a better outcome.

    Time frame: 18 months

  5. Steroid dose after TTFields

    Steroid dose recorded after TTFields until the start of the postoperative RT. Lower (or absence of) dose represents a better outcome.

    Time frame: 18 months

  6. Progression free survival

    Time period from the date of surgery to the date of the MRI scan demonstrating first progression as determined by the neuro-oncology MDT. A longer time period represents a better outcome.

    Time frame: 18 months

  7. Overall survival

    Time period from the date of surgery to the date of death. A longer time period represents a better outcome.

    Time frame: 18 months

  8. Collection of liquid biopsies

    Collection of blood and tear fluid samples at matched imaging timepoints.

    Time frame: 18 months

  9. Skin reactions

    Skin reactions defined by CTCAE V5.0 - a rating scale of 1 to 5. 1 indicates minimal toxicity (skin irritation etc), 5 indicates death - or life threatening complications.

    Time frame: 18 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymised Individual Participant Data (IPD) relating to specified clinical outcomes may be shared upon request. A Sponsor approved Data Management Plan will detail the full sharing criteria and agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Anonymised data will be made freely available following any temporary data embargoes put in place by the funder or from researchers rights to the exclusive use of data (e.g. 6 months).

Access criteria: Appropriate scientific justification, review by Principal Investigator and Trial Management Group, necessary legal contracts e.g. Data Access Agreements in place.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Sep 2026, 20 months after the start.

Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 20 months is below that.

Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2023
First posted
Nov 18, 2023
StartActual
Dec 19, 2024
Primary completionEst.
Sep 3, 2026
CompletionEst.
Dec 30, 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06136611
Collaborators
University of Manchester, Northern Care Alliance NHS Foundation Trust, NovoCure Ltd.
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Dec 19, 2024
Primary completion
Sep 3, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
May 8, 2026

Study contacts

Gerben R Borst, MD PhD
Contact
gerben.borst@nhs.net
0161 446 3000
Melanie Oddy
Contact
0161 446 3000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion